SignalCorporate
Jazz climbs as 2026 revenue guidance boosted
Jazz climbs as 2026 revenue guidance boosted
Context
What happened: Jazz Pharmaceuticals (JAZZ) raised its 2026 revenue forecast and reported Q3 results that beat on the top line. Shares rose about 8% in Tuesday morning trading.
Key numbers: 2026 revenue guidance now $4.775B-$4.85B, up from $4.6B-$4.75B prior. Consensus is $4.8B. Stock up ~8%.
Why it matters: The raised outlook puts the low end of guidance above the prior range, and the top-line beat accompanied the increase.
Coverage: 5 outlets in 24h
What changed
Jazz Pharmaceuticals (JAZZ) raised its 2026 revenue forecast and reported Q3 results that beat on the top line. Shares rose about 8% in Tuesday morning trading.
Why it matters
The raised outlook puts the low end of guidance above the prior range, and the top-line beat accompanied the increase.